Early-stage medical devices company CroíValve has raised €3.2 million oversubscribed seed financing round.
The company, which has developed a minimally invasive device to treat defective heart valves, is a spin-out from Trinity’s Centre for Bioengineering.
Its device is a safe and effective treatment for tricuspid regurgitation, a common heart condition that occurs when valves do not close properly. This causes blood to leak backwards, which can have a significant impact on how the heart functions.